The final stage trial result of Oxford’s COVID-19 vaccine candidate should definitely be known by Christmas, the chief investigator on the study said on Thursday, adding it was too early to know its efficacy yet.
When asked if it was too early to say whether the vaccine will stops disease developing Andrew Pollard, director of the Oxford Vaccine Group, said: “We haven’t quite got to that point yet. We’re obviously not going to rush that.”
He said: “We’re getting close, and it’s definitely going to be before Christmas, based on the progress.”
